Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Pacira BioSciences to Participate in Fireside Chat at the Barclays Global Healthcare Conference
08:00am, Wednesday, 09'th Mar 2022
TAMPA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Confe
Pacira (PCRX) Rides High in YTD Period on Robust Exparel Sales
03:23pm, Monday, 07'th Mar 2022 Zacks Investment Research
Pacira's (PCRX) flagship product, Exparel, has been performing well since its launch. The company's efforts to expand the drug's label also holds promise.
Pacira (PCRX) Rides High in YTD Period on Robust Exparel Sales
12:00pm, Monday, 07'th Mar 2022
Pacira's (PCRX) flagship product, Exparel, has been performing well since its launch. The company's efforts to expand the drug's label also holds promise.
Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
04:09pm, Friday, 25'th Feb 2022 Zacks Investment Research
Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.
Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
12:16pm, Friday, 25'th Feb 2022
Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
01:01pm, Thursday, 24'th Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Adagio Appoints COO David Hering As Interim CEO
Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th
Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q4 2021 Results - Earnings Call Transcript
12:36pm, Thursday, 24'th Feb 2022
Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q4 2021 Results - Earnings Call Transcript
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
01:06pm, Sunday, 20'th Feb 2022 Benzinga
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
On the regulatory front, the Food and Drug A
Earnings Preview: Pacira (PCRX) Q4 Earnings Expected to Decline
08:02pm, Thursday, 17'th Feb 2022 Zacks Investment Research
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacira to Report 2021 Financial Results on Thursday February 24, 2022
01:00pm, Wednesday, 16'th Feb 2022 GlobeNewswire Inc.
TAMPA, Fla., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2021 financial results before
Pacira to Report 2021 Financial Results on Thursday February 24, 2022
08:00am, Wednesday, 16'th Feb 2022
TAMPA, Fla., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2021 financial results before t
Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $37.3 Million for January 2022
01:00pm, Tuesday, 15'th Feb 2022 GlobeNewswire Inc.
-- EXPAREL average daily sales for January 2022 were 104% of January 2021 -- -- EXPAREL average daily sales for January 2022 were 104% of January 2021 --
InMed Pharmaceuticals Inc. (INM) Reports Q2 Loss, Tops Revenue Estimates
01:45am, Tuesday, 15'th Feb 2022 Zacks Investment Research
InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -29.17% and 6%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto
Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating
06:39pm, Monday, 07'th Feb 2022 Investor''s Business Daily
A Relative Strength Rating upgrade for Pacira Pharmaceuticals shows improving technical performance. Will it continue?
Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report?
05:10pm, Friday, 04'th Feb 2022 Zacks Investment Research
Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
